• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

miRNA-223 通过靶向 EGFR 抑制 PI3K/AKT 通路从而成为人类非小细胞肺癌的抑癌基因。

miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR.

机构信息

Department of Respiratory Medicine, Jining First People's Hospital, Jining, Shandong 272111, P.R. China.

Department of Otorhinolaryngology, Jining First People's Hospital, Jining, Shandong 272111, P.R. China.

出版信息

Oncol Rep. 2019 Mar;41(3):1549-1559. doi: 10.3892/or.2019.6983. Epub 2019 Jan 24.

DOI:10.3892/or.2019.6983
PMID:30747217
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6365711/
Abstract

The present study aimed to further explore the molecular mechanisms of miRNA-223 in non-small cell lung cancer (NSCLC). Data prospectively collected from NSCLC patients and volunteers from March 2016 to MayMAP2016 at Tsinghua Changgung Hospital were analyzed. Cell proliferation was measured using MTT assay, while cell apoptosis and caspase-3/9 activity were measured using flow cytometry and caspase-3/9 activity kit. Bax, EGFR, PI3K and p-Akt protein were also investigated using western blotting. The results revealed that the serum levels of miRNA-223 in NSCLC patients were downregulated. In an inMAPvitro model, over-expression of miRNA-223 induced apoptosis while reducing cell proliferation. In contrast, downregulation of the expression of miRNA-223 inhibited apoptosis whereas it increased cell proliferation. Meanwhile, overexpression of miRNA-223 suppressed the protein expression of EGFR, PI3K and p-Akt in NSCLC cells. An EGFR inhibitor promoted the anticancer effects of miRNA-223 in NSCLC cells through the EGFR/PI3K/AKT pathway. Meanwhile, a PI3K inhibitor increased the anticancer effects of miRNA-223 in NSCLC cells through the PI3K/AKT pathway. Thus, a new pathway has been identified in the present study, and application of miRNA-223 may induce the apoptosis of NSCLC through the PI3K/AKT pathway by EGFR.

摘要

本研究旨在进一步探讨 miRNA-223 在非小细胞肺癌（NSCLC）中的分子机制。分析了 2016 年 3 月至 5 月清华长庚医院 NSCLC 患者和志愿者前瞻性收集的数据。使用 MTT 测定法测量细胞增殖，使用流式细胞术和 caspase-3/9 活性试剂盒测量细胞凋亡和 caspase-3/9 活性。还使用 Western blot 检测 Bax、EGFR、PI3K 和 p-Akt 蛋白。结果显示，NSCLC 患者血清中 miRNA-223 的水平下调。在体外模型中，miRNA-223 的过表达诱导细胞凋亡，同时减少细胞增殖。相反，miRNA-223 表达下调抑制细胞凋亡，而增加细胞增殖。同时，miRNA-223 的过表达抑制 NSCLC 细胞中 EGFR、PI3K 和 p-Akt 的蛋白表达。EGFR 抑制剂通过 EGFR/PI3K/AKT 通路增强 miRNA-223 在 NSCLC 细胞中的抗癌作用。同时，PI3K 抑制剂通过 PI3K/AKT 通路增加 miRNA-223 在 NSCLC 细胞中的抗癌作用。因此，本研究确定了一条新的通路，应用 miRNA-223 通过 EGFR 可能通过 PI3K/AKT 通路诱导 NSCLC 细胞凋亡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/db5404283413/OR-41-03-1549-g10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/11f9527a219b/OR-41-03-1549-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/f322108f37cd/OR-41-03-1549-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/18b8a7552778/OR-41-03-1549-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/411827cf11b6/OR-41-03-1549-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/61a20f885d43/OR-41-03-1549-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/7a9affb6ea43/OR-41-03-1549-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/b07badc6f169/OR-41-03-1549-g08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/d60376d139c4/OR-41-03-1549-g09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/db5404283413/OR-41-03-1549-g10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/11f9527a219b/OR-41-03-1549-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/f322108f37cd/OR-41-03-1549-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/18b8a7552778/OR-41-03-1549-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/411827cf11b6/OR-41-03-1549-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/61a20f885d43/OR-41-03-1549-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/7a9affb6ea43/OR-41-03-1549-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/b07badc6f169/OR-41-03-1549-g08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/d60376d139c4/OR-41-03-1549-g09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d175/6365711/db5404283413/OR-41-03-1549-g10.jpg

相似文献

1
miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR.miRNA-223 通过靶向 EGFR 抑制 PI3K/AKT 通路从而成为人类非小细胞肺癌的抑癌基因。
Oncol Rep. 2019 Mar;41(3):1549-1559. doi: 10.3892/or.2019.6983. Epub 2019 Jan 24.
2
miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3β signaling pathway.微小RNA-125b通过PI3K/Akt/GSK3β信号通路调节人非小细胞肺癌的细胞凋亡。
Oncol Rep. 2017 Sep;38(3):1715-1723. doi: 10.3892/or.2017.5808. Epub 2017 Jul 12.
3
MicroRNA‑145 inhibits migration and induces apoptosis in human non‑small cell lung cancer cells through regulation of the EGFR/PI3K/AKT signaling pathway.微小 RNA-145 通过调控 EGFR/PI3K/AKT 信号通路抑制人非小细胞肺癌细胞迁移并诱导其凋亡。
Oncol Rep. 2018 Nov;40(5):2944-2954. doi: 10.3892/or.2018.6666. Epub 2018 Aug 23.
4
Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.微小RNA-135a通过IGF-1/PI3K/Akt信号通路对非小细胞肺癌细胞增殖、迁移、侵袭、凋亡及肿瘤血管生成的影响
Cell Physiol Biochem. 2017;42(4):1431-1446. doi: 10.1159/000479207. Epub 2017 Jul 17.
5
Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.miRNA-133b 的过度调控通过靶向 EGFR 抑制顺铂诱导的非小细胞肺癌细胞的增殖，该调控作用是通过 PI3K/Akt 和 JAK2/STAT3 信号通路实现的。
Oncol Rep. 2018 Mar;39(3):1227-1234. doi: 10.3892/or.2018.6215. Epub 2018 Jan 15.
6
MicroRNA-126 Targeting PIK3R2 Inhibits NSCLC A549 Cell Proliferation, Migration, and Invasion by Regulation of PTEN/PI3K/AKT Pathway.靶向PIK3R2的MicroRNA-126通过调控PTEN/PI3K/AKT信号通路抑制非小细胞肺癌A549细胞的增殖、迁移和侵袭
Clin Lung Cancer. 2016 Sep;17(5):e65-e75. doi: 10.1016/j.cllc.2016.03.012. Epub 2016 Apr 6.
7
LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.长链非编码 RNA HULC 通过上调鞘氨醇激酶 1（SPHK1）及其下游的 PI3K/Akt 通路促进非小细胞肺癌细胞增殖并抑制细胞凋亡。
Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8722-8730. doi: 10.26355/eurrev_201812_16637.
8
Circular RNA circ‑ACACA regulates proliferation, migration and glycolysis in non‑small‑cell lung carcinoma via miR‑1183 and PI3K/PKB pathway.环状 RNA circ-ACACA 通过 miR-1183 和 PI3K/PKB 通路调控非小细胞肺癌细胞的增殖、迁移和糖酵解。
Int J Mol Med. 2020 Jun;45(6):1814-1824. doi: 10.3892/ijmm.2020.4549. Epub 2020 Mar 24.
9
Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the PI3K/ Akt/NF-κB Signaling Pathway in Vitro and in Vivo.miR-21通过在体外和体内抑制PI3K/Akt/NF-κB信号通路对肺癌细胞凋亡的影响
Cell Physiol Biochem. 2018;46(3):999-1008. doi: 10.1159/000488831. Epub 2018 Apr 13.
10
MicroRNA‑21 increases cell viability and suppresses cellular apoptosis in non‑small cell lung cancer by regulating the PI3K/Akt signaling pathway.MicroRNA-21 通过调控 PI3K/Akt 信号通路增加非小细胞肺癌细胞活力并抑制细胞凋亡。
Mol Med Rep. 2017 Nov;16(5):6506-6511. doi: 10.3892/mmr.2017.7440. Epub 2017 Sep 8.

引用本文的文献

1
MicroRNA155 in non-small cell lung cancer: a potential therapeutic target.非小细胞肺癌中的微小RNA155：一个潜在的治疗靶点。
Front Oncol. 2025 Feb 3;15:1517995. doi: 10.3389/fonc.2025.1517995. eCollection 2025.
2
Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer.微小RNA对非小细胞肺癌的调控作用及治疗潜力
Heliyon. 2023 Nov 14;9(11):e22080. doi: 10.1016/j.heliyon.2023.e22080. eCollection 2023 Nov.
3
Epigenetic regulation in lung cancer.肺癌中的表观遗传调控。

本文引用的文献

1
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.辅助化疗联合或不联合贝伐单抗用于可切除的非小细胞肺癌患者（E1505）：一项开放标签、多中心、随机、3期试验。
Lancet Oncol. 2017 Dec;18(12):1610-1623. doi: 10.1016/S1470-2045(17)30691-5. Epub 2017 Nov 9.
2
Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials.厄洛替尼联合靶向治疗与厄洛替尼单药治疗既往接受过治疗的晚期非小细胞肺癌的疗效比较：一项来自24项随机对照试验的荟萃分析
Oncotarget. 2017 May 31;8(42):73258-73270. doi: 10.18632/oncotarget.18319. eCollection 2017 Sep 22.
3
MedComm (2020). 2023 Oct 26;4(6):e401. doi: 10.1002/mco2.401. eCollection 2023 Dec.
4
Rebound increase in microRNA levels at the end of 5-FU-based therapy in colorectal cancer patients.结直肠癌患者接受 5-FU 为基础的治疗结束时微小 RNA 水平的反弹增加。
Sci Rep. 2023 Aug 30;13(1):14237. doi: 10.1038/s41598-023-41030-7.
5
Mutational Damages in Malignant Lung Tumors.恶性肺肿瘤中的突变损伤。
Asian Pac J Cancer Prev. 2023 Feb 1;24(2):709-716. doi: 10.31557/APJCP.2023.24.2.709.
6
MicroRNA-21-5p Reduces Hypoxia/Reoxygenation-Induced Neuronal Cell Damage through Negative Regulation of CPEB3.微小 RNA-21-5p 通过负向调控 CPEB3 减少低氧/复氧诱导的神经元细胞损伤。
Anal Cell Pathol (Amst). 2021 Dec 2;2021:5543212. doi: 10.1155/2021/5543212. eCollection 2021.
7
Effect of BRAF-mediated PI3K/Akt/mTOR pathway on biological characteristics and chemosensitivity of NSCLC A549/DDP cells.BRAF介导的PI3K/Akt/mTOR通路对非小细胞肺癌A549/DDP细胞生物学特性及化疗敏感性的影响
Oncol Lett. 2021 Aug;22(2):584. doi: 10.3892/ol.2021.12845. Epub 2021 Jun 3.
8
In Vitro Evaluation of the Neuroprotective Effect of Saponins by Activating the EGFR/PI3K/AKT Pathway.通过激活EGFR/PI3K/AKT途径对皂苷神经保护作用的体外评估
Evid Based Complement Alternat Med. 2020 Jul 31;2020:1403572. doi: 10.1155/2020/1403572. eCollection 2020.
9
MiR-1299 Impedes the Progression of Non-Small-Cell Lung Cancer Through EGFR/PI3K/AKT Signaling Pathway.微小RNA-1299通过表皮生长因子受体/磷脂酰肌醇-3-激酶/蛋白激酶B信号通路抑制非小细胞肺癌进展。
Onco Targets Ther. 2020 Jul 30;13:7493-7502. doi: 10.2147/OTT.S250396. eCollection 2020.
10
miR-516a-3p promotes proliferation, migration, and invasion and inhibits apoptosis in lung adenocarcinoma by targeting PTPRD.微小RNA-516a-3p通过靶向蛋白酪氨酸磷酸酶受体D促进肺腺癌的增殖、迁移和侵袭并抑制其凋亡。
Int J Clin Exp Pathol. 2019 Nov 1;12(11):4222-4231. eCollection 2019.
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.一项关于pictilisib联合紫杉醇和卡铂（含或不含贝伐单抗）或培美曲塞和顺铂（含或不含贝伐单抗）用于晚期非小细胞肺癌患者的安全性和药代动力学的1B期剂量递增研究。
Eur J Cancer. 2017 Nov;86:186-196. doi: 10.1016/j.ejca.2017.08.027. Epub 2017 Oct 6.
4
ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.ING5基因敲低通过表皮生长因子受体/磷脂酰肌醇-3激酶/蛋白激酶B（EGFR/PI3K/Akt）和白细胞介素-6/信号转导子和转录激活子3（IL-6/STAT3）信号通路诱导上皮-间质转化（EMT），从而增强肺癌细胞的迁移和侵袭能力。
Oncotarget. 2017 Apr 21;8(33):54265-54276. doi: 10.18632/oncotarget.17346. eCollection 2017 Aug 15.
5
The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b.长链非编码 RNA H19 通过差异海绵吸附 miR-200b/c 和 let-7b 来介导 EMT 和 MET 可塑性中的乳腺癌细胞可塑性。
Sci Signal. 2017 Jun 13;10(483):eaak9557. doi: 10.1126/scisignal.aak9557.
6
MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion.伴有表皮生长因子受体第19外显子缺失的肺腺癌的微小RNA特征
J Cancer. 2017 May 11;8(7):1311-1318. doi: 10.7150/jca.17817. eCollection 2017.
7
Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients.液滴数字PCR改善了非小细胞肺癌患者胸水样本中表皮生长因子受体（EGFR）突变的诊断。
Clin Chim Acta. 2017 Aug;471:177-184. doi: 10.1016/j.cca.2017.06.007. Epub 2017 Jun 8.
8
Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significance.循环游离DNA中表皮生长因子受体（EGFR）突变对EGFR突变型转移性肺癌患者的动态监测：耐药性的早期检测及预后意义
Oncol Lett. 2017 Jun;13(6):4549-4557. doi: 10.3892/ol.2017.6022. Epub 2017 Apr 11.
9
MicroRNA-17-5p inhibits proliferation and triggers apoptosis in non-small cell lung cancer by targeting transforming growth factor β receptor 2.微小RNA-17-5p通过靶向转化生长因子β受体2抑制非小细胞肺癌的增殖并引发凋亡。
Exp Ther Med. 2017 Jun;13(6):2715-2722. doi: 10.3892/etm.2017.4347. Epub 2017 Apr 18.
10
Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients.随机试验比较肺癌患者的网络介导随访与常规监测。
J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx029.